Similarly, MCF7-LTED xenograft growth (tumor volume) was not affected by daily ABT-263 treatment (Fig. 1h), even though Bim/Bcl-2 interactions were disrupted by ABT-263 (Supplemental Fig. 2a). Here, BCL2 is linked to neoplasm.